Blackrock’s Sending THIS Crypto Higher on Purpose

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

Kate Bingham Biography and Net Worth

Director of Bicycle Therapeutics

Ms. Kate Bingham is the Director of Bicycle Therapeutics. She is 59 years old.

How do I contact Kate Bingham?: The corporate mailing address for Ms. Bingham and other Bicycle Therapeutics executives is B900 BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0, CB22 3AT. Bicycle Therapeutics can also be reached via phone at 441223261503 and via email at [email protected]. Learn More on Kate Bingham's contact information.
Has Kate Bingham been buying or selling shares of Bicycle Therapeutics?: Kate Bingham has not been actively trading shares of Bicycle Therapeutics over the course of the past ninety days. Most recently, Kate Bingham sold 600 shares of the business's stock in a transaction on Tuesday, July 13th. The shares were sold at an average price of $33.50, for a transaction totalling $20,100.00. Learn More on Kate Bingham's trading history.
Who are Bicycle Therapeutics' active insiders?: Bicycle Therapeutics' insider roster includes Stephen Alexander (SVP), Kate Bingham (Director), Nigel Crockett (Insider), Lee Kalowski (CFO), Nicholas Keen (Insider), Kevin Lee (CEO), and Pierre Legault (Director). Learn More on Bicycle Therapeutics' active insiders.
Are insiders buying or selling shares of Bicycle Therapeutics?: In the last twelve months, insiders at the sold shares 17 times. They sold a total of 32,657 shares worth more than $683,852.68. The most recent insider tranaction occured on November, 11th when CAO Travis Alvin Thompson sold 6,256 shares worth more than $157,088.16. Insiders at Bicycle Therapeutics own 8.5% of the company. Learn More about insider trades at Bicycle Therapeutics.
Information on this page was last updated on 11/11/2024.

Kate Bingham Insider Trading History at Bicycle Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/13/2021	Sell	600	$33.50	$20,100.00

Kate Bingham Buying and Selling Activity at Bicycle Therapeutics

Bicycle Therapeutics Company Overview

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Today's Range

Now: $20.40

$20.06

$20.71

50 Day Range

MA: $24.37

$20.46

$27.51

2 Week Range

Now: $20.40

$13.31

$28.67

Volume

10,186 shs

Average Volume

357,084 shs

Market Capitalization

$970.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.89